Short answer · Medically reviewed summary · Last updated: 2026-04-07
TL;DR: Neurofibromatosis, specifically the type now known as NF1, was first systematically described by Friedrich Daniel von Recklinghausen in 1882, though medical literature contains accounts of the condition dating back to the 13th century. Our understanding of the disease has evolved from viewing it as a mere collection of skin tumors to recognizing it as a complex, multisystem genetic disorder driven by mutations in tumor suppressor genes. When was Neurofibromatosis first identified? While the history of Neurofibromatosis stretches back centuries—with early historical accounts appearing in the 13th century—it was not formally defined until the late 19th century.
1 people with Neurofibromatosis have shared their first-person experience on this question at DiseaseMaps.
What is the history of Neurofibromatosis?
History of Neurofibromatosis: when and how it was discovered, and the milestones in research since, medically reviewed.
TL;DR: Neurofibromatosis, specifically the type now known as NF1, was first systematically described by Friedrich Daniel von Recklinghausen in 1882, though medical literature contains accounts of the condition dating back to the 13th century. Our understanding of the disease has evolved from viewing it as a mere collection of skin tumors to recognizing it as a complex, multisystem genetic disorder driven by mutations in tumor suppressor genes.
When was Neurofibromatosis first identified?
While the history of Neurofibromatosis stretches back centuries—with early historical accounts appearing in the 13th century—it was not formally defined until the late 19th century. The most significant historical milestone occurred in 1882 when German pathologist Friedrich Daniel von Recklinghausen published his seminal work, Über die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen. He correctly identified that the skin tumors and nerve growths associated with the condition were related, which is why Neurofibromatosis type 1 (NF1) was historically termed "von Recklinghausen's disease."
How has our understanding of the condition evolved?
For nearly a century after von Recklinghausen, Neurofibromatosis was often misunderstood as a single, uniform condition. It was not until the late 20th century, specifically through the 1987 National Institutes of Health (NIH) Consensus Development Conference, that the medical community formally distinguished between NF1 and NF2 (Neurofibromatosis type 2). Modern molecular genetics further revolutionized the field by identifying the specific genes responsible: the NF1 gene on chromosome 17 (discovered in 1990) and the NF2 gene on chromosome 22 (discovered in 1993). These discoveries shifted the medical perspective from purely descriptive clinical observations to a deep understanding of the molecular pathways that cause tumor growth.
What were the historical misconceptions about Neurofibromatosis?
Historically, patients with Neurofibromatosis faced significant social stigma and medical neglect. Before the mid-20th century, the condition was frequently misidentified or confused with other dermatological or neurological disorders. Because the physical manifestations of Neurofibromatosis can be highly visible, patients were often marginalized. Furthermore, early diagnostic criteria were broad and failed to capture the wide spectrum of severity, leading to fragmented care. Today, we know that the condition varies drastically from person to person, and our approach has shifted toward personalized, multidisciplinary monitoring.
Major milestones in clinical research and patient advocacy
The evolution of care for this condition is marked by several key developments:
- 1882: Friedrich Daniel von Recklinghausen publishes the first comprehensive clinical description.
- 1990: Scientists identify the NF1 gene, enabling genetic testing and a better understanding of the RAS-MAPK pathway.
- 2020: The FDA approves the first targeted therapy for pediatric patients with symptomatic, inoperable plexiform neurofibromas, representing a massive shift from "watch and wait" to active medical intervention.
- Community Growth: Organizations like those represented on DiseaseMaps.org have empowered the 725+ community members with Neurofibromatosis to share experiences, which has accelerated clinical trial recruitment and patient-centered research.
Next steps
- Consult with a genetic counselor to understand the inheritance patterns of Neurofibromatosis within your family.
- Connect with the 725 members of the DiseaseMaps.org community to share lived experiences and coping strategies.
- Stay informed about new clinical trials through the Children’s Tumor Foundation or the NIH GARD portal.
- Ensure your care team includes specialists such as neurologists, dermatologists, and oncologists familiar with current NF management guidelines.
Medical disclaimer: This information is for educational purposes and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.
References
- NIH Genetic and Rare Diseases (GARD) Information Center: Neurofibromatosis.
- Orphanet: Rare Disease Database - Neurofibromatosis type 1.
- Online Mendelian Inheritance in Man (OMIM): Entry #162200 (NF1).
- Children’s Tumor Foundation: History and Research Milestones.
The term "neurofibromatosis" comprises a certain number of genetic diseases affecting the cell growth of neural tissues. There are two types of neurofibromatosis : type I and type II. These two forms have similar features and are caused by mutations in different genes.
Type I neurofibromatosis is a dysplasia neurodermal or an abnormality in the development of neuronal tissue. This condition was first described in 1882 by Friederich Daniel Von Recklinghausen, where the current name of this pathology.
The alterations of the neural tissue appear from the embryonic development.
Neurofibromatosis type I is the most common form of neurofibromatosis with 90 % of the cases are of type I. It is also a human genetic disease the most common with a prevalence (number of cases in a given population at a given time), amounting to 1/3, 000 births. Moreover, no predominance was observed between men and women. (2)
The disease of Recklinghausen, is a hereditary genetic disease whose mode of transmission is autosomal dominant. Or, a key chromosome non-sexual and that the presence of only one of the two copies of the mutated gene is sufficient for the subject to develop the disease. This disease is the consequence of alterations at the level of the NF1 gene located on chromosome 17q11.2.
Posted Oct 11, 2017 by Robert 1750
